Accepted into StartX Spring 2026, AI-Stroke advances U.S. EMS stroke research with new advisors, clinical studies, and ...
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
BIRMINGHAM, AL, UNITED STATES, January 8, 2026 / EINPresswire.com / — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the launch ...
Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, ...
Phase 3 SELVA study evaluating QTORINâ„¢ rapamycin 3.9% anhydrous gel (QTORINâ„¢ rapamycin) for microcystic lymphatic ...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...
Scott Drutman Incoming Chief Medical Officer of Enara Bio Boehringer Ingelheim exercises option to license additional Dark ...
MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing in ...
Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...
As clinical diagnostics become a central force in shaping therapies and driving innovation, healthcare leaders must prepare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback